Phase II Trial: Olaparib + Abiraterone vs Placebo + Abiraterone for Metastatic CRPC Following Chemotherapy

June 1-5, 2018; Chicago, Illinois
Combination of a PARP inhibitor plus ADT increases radiologic PFS in patients with docetaxel-treated mCRPC.
Format: Microsoft PowerPoint (.ppt)
File Size: 234 KB
Released: June 3, 2018

Acknowledgements

Jointly provided by Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ACHS Logo

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
Astellas
AstraZeneca
Celgene Corporation
Eisai
Genentech
Janssen Therapeutics
Merck & Co., Inc.
Seattle Genetics

Related Content

Cabozantinib plus atezolizumab suggested encouraging anticancer activity in metastatic castration-resistant prostate cancer; ESMO coverage from Clinical Care Options (CCO)

Eva M. Ciruelos, MD, PhD Karim Fizazi, MD, PhD Eric Van Cutsem, MD, PhD person default Vamsidhar Velcheti, MD Released: September 21, 2021

Download this short slideset from Clinical Care Options (CCO) the use of androgen deprivation therapy for nonmetastatic or metastatic prostate cancer

Daniel W. Lin, MD Alicia K. Morgans, MD, MPH David F. Penson, MD Released: September 20, 2021

Experts highlight key studies being presented at the upcoming 2021 ESMO Congress in this commentary from Clinical Care Options (CCO)

Eva M. Ciruelos, MD, PhD Karim Fizazi, MD, PhD Eric Van Cutsem, MD, PhD person default Vamsidhar Velcheti, MD Released: September 15, 2021

Slides from Clinical Care Options (CCO) on 2021 treatment recommendations for patients with nmCRPC.

David F. Penson, MD Released: September 10, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue